Implantica presents the third quarter 2024 on November 15 at 15

    101 Aufrufe 101 0 Kommentare 0 Kommentare

    00 CEST

    VADUZ, Liechtenstein, Nov. 8, 2024 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2024 at 15:00 CET on November 15. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.

    The presentation will be in English via an audiocast with teleconference:

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Nasdaq Stock Market Inc!
    Long
    72,55€
    Basispreis
    0,77
    Ask
    × 9,81
    Hebel
    Zum Produkt
    Short
    87,42€
    Basispreis
    0,77
    Ask
    × 9,56
    Hebel
    Zum Produkt
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    If you wish to participate via webcast, please use the following link:

    • https://ir.financialhearings.com/implantica-q3-report-2024

    If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.

    • https://conference.financialhearings.com/teleconference/?id=50049903

    Speakers:

    • CEO Peter Forsell
    • CFO Andreas Öhrnberg
    • Chief Corporate Affairs Officer Nicole Pehrsson

    For further information, please contact:
    Nicole Pehrsson, Investor Relations
    Telephone (CH): +41 (0)79 335 09 49
    nicole.pehrsson@implantica.com

    Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

    The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

    The information was sent for publication, through the agency of the contact person set out above, on November 8, 2024 at 11:50 a.m. CET.

    About Implantica

    Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/implantica/r/implantica-presents-the-third-quarter-2024-on-november-15-at-15-00-cest,c4063573

    The following files are available for download:

    https://mb.cision.com/Main/19732/4063573/3101703.pdf

    Implantica presents the third quarter 2024 on November 15 at 15:00 CEST

     

    Cision View original content:https://www.prnewswire.co.uk/news-releases/implantica-presents-the-third-quarter-2024-on-november-15-at-1500-cest-302299862.html




    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Implantica presents the third quarter 2024 on November 15 at 15 00 CEST VADUZ, Liechtenstein, Nov. 8, 2024 /PRNewswire/ - Implantica AG (publ) invites investors to a presentation of the third quarter 2024 at 15:00 CET on November 15. The interim report for the third quarter will be published at 8:00 a.m. CET on the same …